To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Researchers from SPI, in collaboration with teams from an European foundation, EF Clif, carried out global and targeted metabolomic analyzes which made possible to highlight, in cirrhotic patients, an activation of the kynurenine metabolic pathway (tryptophan degradation pathway). The imbalance of this pathway is probably the cause of the symptoms observed during cirrhotic decompensation, when the body can no longer compensate for liver dysfunctions.
Europe is committed to better diagnostic and therapeutic management of patients with severe forms of cirrhosis. It finances the MICROB-PREDICT consortium, which aims to better understand the role of the human microbiome in the pathogenesis and evolution of cirrhosis. Final goal is to uture personalized therapeutic strategies and diagnostic tools. The SPI (Joliot Institute) is the main project lead for the CEA.
By using in vivo MRI, researchers at NeuroSpin (GIN-Bordeaux) have been able to evaluate the myelination of nerve fibers in the auditory cortex, area of the brain involved in the processing of language sounds. They observed an asymmetry of myelination in favor of the left hemisphere, in particular according to language performances. They show the usefulness of neuroimaging markers in the study of structure-function relationships at the cerebral cortex level.
Helicenes are synthetic molecules with attractive properties for physicists expert in materials but also for biologists. A collaboration led by chemists from the SCBM (CEA-Joliot) and involving the NIMBE (CEA-Iramis) allowed the synthesis of a particular class of helicenes.
A partnership between the François Jacob Institute of Biology/CEA, The Frédéric Joliot Institute for Life Sciences/CEA and CellTechs (a Sup'Biotech lab) has led to a new approach for modeling Alzheimer's disease in vitro.
Researchers from the SCBM and the IRAMIS (CEA/CNRS) have develop a 14C labeling method for therapeutic molecules based on dynamic Misspelled Wordcarbone dioxide exchange. This one step method generates far less radioactive waste. By facilitating some preclinical and clinical steps, it should eventually help to speed up the marketing applications of some new drug discoveries.
A collaboration involving the Sainte-Anne Hospital, the SHFJ, the Saint-Antoine research center and the ICM identified, through a PET brain imaging study in patients with Alzheimer's disease, two distinct kinetic profiles of the cerebral neuroimmune response, that impact the disease progression differently. Researchers propose an original model of neuroinflammation, likely to open new therapeutic avenues.
Thanks to complementary imaging techniques, researchers from the SHFJ and NeuroSpin have shown that the physical blood-brain barrier (BBB) disruption is not necessarly enough to deliver some drugs into the brain, especially when there are recognized and supported by efflux transporters.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.